Interestingly, Jacoby et al. [150] observed that in pre-B cell ALL in in vivo murine models, persistent CD19 CART cell therapy resulted in a myeloid lineage switch characterized by the loss of CD19. Here, CD19 is linked to acute lymphoblastic leukemia.